Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676732 | 1.00 | HDAC8 (0.48) | HDAC8MEN1KMT2APTPN1NR1D1 | |
| SCHEMBL18793351 | 1.00 | HDAC8 (0.48) | HDAC8MEN1KMT2APTPN1NR1D1 | |
| SCHEMBL6853856 | 0.86 | ESR2 (0.52) | HDAC8MEN1KMT2APTPN1NR1H2 | |
| SCHEMBL17573049 | 0.86 | HDAC8 (0.47) | HDAC8MEN1KMT2APTPN1NR1H2 | |
| SCHEMBL19460717 | 0.86 | HDAC8 (0.47) | HDAC8MEN1KMT2APTPN1NR1H2 | |
| SCHEMBL19329091 | 0.86 | MEN1 (0.44) | HDAC8MEN1KMT2APTPN1TACR1 | |
| SCHEMBL19329093 | 0.86 | MEN1 (0.44) | HDAC8MEN1KMT2APTPN1TACR1 | |
| SCHEMBL6394031 | 0.85 | NR1H2 (0.59) | HDAC8MEN1KMT2APTPN1NR1H2 | |
| SCHEMBL29798888 | 0.85 | MEN1 (0.46) | HDAC8MEN1KMT2APTPN1NR1H2 | |
| SCHEMBL2732550 | 0.85 | MEN1 (0.46) | HDAC8MEN1KMT2APTPN1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HDAC8 2989/4885MEN1 1644/4885KMT2A 968/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HDAC8 2989/4885MEN1 1644/4885KMT2A 968/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HDAC8 2989/4885MEN1 1644/4885KMT2A 968/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HDAC8 3087/4885MEN1 1766/4885KMT2A 997/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HDAC8 2989/4885MEN1 1644/4885KMT2A 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.